Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis
Metrics: PDF 1005 views | HTML 1479 views | ?
Guoming Hu1 and Shimin Wang2
1Department of General Surgery, Breast and Thyroid Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China
2Department of Nephrology, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China
Guoming Hu, email: email@example.com
Keywords: tumor-infiltrating CD57+ lymphocytes; favorable outcome; solid tumor; meta-analysis
Received: October 20, 2017 Accepted: November 27, 2017 Published: December 22, 2017
The prognostic role of tumor-infiltrating CD57-positive lymphocytes (CD57+ lymphocytes) in human solid tumors remains controversial. Herein, we conducted a meta-analysis including 26 published studies with 7656 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor-infiltrating CD57+ lymphocytes in human solid tumors. We found that CD57+ lymphocyte infiltration significantly improved overall survival (OS) including 1 – year, 3 – year and 5 – year survival, and disease – free survival (DFS) in all types of solid tumors. In stratified analyses, CD57+ lymphocyte infiltration was significantly associated with better OS in hepatocellular, esophageal, head and neck carcinoma, non-small cell lung cancer, 5 – year survival in colorectal cancer, and 3 – year and 5 – year survival in gastric cancer, but not with 1 – year survival in gastric cancer, or 1 – year or 3 – year survival in colorectal cancer. In addition, high density of intratumoral CD57+ lymphocytes was significantly inversely correlated with lymph node metastasis and TNM stage of solid tumor. In conclusion, CD57+ lymphocyte infiltration leads to a favorable clinical outcome in solid tumors, implicating that it is a useful biomarker for prognosis and adoptive immunotherapy based on these cells may be a promising choice for treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.